President's Page: Employing Shared Decision-Making Models to Improve Care and Patient Value: A Cardiovascular Professional Initiative  by Brindis, Ralph & Spertus, John A.
P
M
V
I
t
g
h
h
o
c
s
e
f
t
b
b
h
a
p
e
n
o
s
t
e
e
e
c
i
m
e
m
c
A
d
m
t
Journal of the American College of Cardiology Vol. 56, No. 24, 2010
© 2010 by the American College of Cardiology Foundation ISSN 0735-1097/$36.00
Published by Elsevier Inc. doi:10.1016/j.jacc.2010.11.004ACC NEWSresident’s Page: Employing Shared Decision-
aking Models to Improve Care and Patient
alue: A Cardiovascular Professional Initiative
Ralph Brindis,
MD, MPH, FACC
ACC President
John A. Spertus,
MD, MPH, FACC
Lauer/Missouri Endowed
Chair at Saint Luke’s
Mid America Heart
Institute/UMKC;
Co-Founder Health
Outcomes Sciences, LLC
Our profession is
thus poised to make
substantial contribu-
tions to the entire
health care system by
developing methods
to support shared
decision-making.n their book “Redefining Health Care,” Michael Porter and Elizabeth Olmsted
Teisberg wrote that when it comes to improving health care delivery, “the right
objective for health care is to increase value for patients, which is the quality of pa-
ient outcomes relative to the dollars expended” (1). This is an obvious and laudable
oal. The challenge, however, lies in determining what defines “value” for patients and
ow that value can be maximized within the routine flow of patient care.
An increasingly important concept garnering attention among both policy makers and
ealth care professionals is shared decision-making. Shared decision-making is “the process
f interacting with patients who wish to be involved in arriving at an informed, values-based
hoice among two or more medically reasonable alternatives” (2). In its recent report to the
ecretary of the Department of Health and Human Services, the National Quality Forum
mphasized the goal of shared decision-making, by explicitly stating that “all patients, their
amilies, and their caregivers [should] have access to information and assistance that enables
hem to make shared and informed decisions about their treatment options” (3). No field
etter represents the opportunity to achieve this goal than cardiology.
Cardiovascular disease is not only the largest cause of mortality for men and women,
ut it also substantially impairs the quality of life of afflicted individuals. Moreover, we
ave numerous diagnostic and therapeutic strategies with which to assess our patients
nd improve their outcomes. However, many of our treatments alter risk without im-
acting outcomes (e.g., the number needed to treat with statins to prevent an event can
xceed 100); improve quality of life without improving survival (e.g., percutaneous coro-
ary intervention [PCI] for stable angina); or improve survival while diminishing quality
f life (e.g., implantable cardiac-defibrillators [ICDs] in patients with inappropriate
hocks and no fatal arrhythmias). Thus, although some patients may want to fully avail
hemselves of cardiac treatments, others, based upon their age, comorbidities, or prefer-
nces, may not. Our profession is thus poised to make substantial contributions to the
ntire health care system by developing methods to support shared decision-making.
Successfully supporting shared decision-making requires several critical components:
stimating patients’ outcomes as a function of their individual risks, defining these out-
omes as a function of alternative treatments, and sharing this information with patients
n a manner that they can understand. Accomplishing these tasks moves health care
uch closer to the Institute of Medicine’s vision for a safer, evidence-based, equitable,
fficient, patient-centered system (4). To accomplish the first 2 tasks, cardiology has nu-
erous clinical trials and observational registries from which prediction models of out-
omes (survival, hospital admissions, or quality of life) can be generated. In fact, the
merican College of Cardiology already has several risk models from our National Car-
iovascular Data Registry (NCDR) that are poised to serve as valuable supports for
edical decision-making if integrated into the routine flow of patient care.
Although one could consider the utility of shared decision-making tools in selectingreatment approaches for coronary disease (medicines alone, PCI, or coronary artery by-
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December 7, 2010:2046–8 President’s Pageass grafting), heart failure (resynchronization therapy,
eft ventricular assist devices, ICDs), atrial fibrillation
rate vs. rhythm control or ablation), or peripheral/carotid
rtery disease (noninvasive vs. peripheral vs. surgical revas-
ularization), even within a given procedure there are nu-
erous opportunities for shared decision-making. As a
ase in point, after a patient has selected PCI there are
lternative treatment strategies that could be supported by
n infrastructure for shared decision-making. For exam-
le, the choice of drug-eluting stents (DES) versus bare-
etal stents has a huge impact on patients. With DES,
atients need to remain on dual antiplatelet therapy for a
onger time (5), and with bare-metal stents, the benefit
aries as a function of a patient’s risk for restenosis (6,7).
roactively engaging patients in such a choice—even one
s seemingly simple as selecting a stent type for PCI—
ight allow patients to have a greater understanding of
heir disease and inspire greater accountability and hope-
ully improved adherence with dual antiplatelet therapy
rescribed after DES placement.
Shared decision-making could be useful when it comes
o medical devices as well, particularly in the cardiovascu-
ar world. By using data already being collected via regis-
ries such as the ICD Registry, cardiovascular profession-
ls could better inform patients of the costs and risks/
enefits of ICDs based on their age and sex. For example,
60-year-old female with heart failure may consider an
CD for primary prevention of sudden cardiac death, as
he life expectancy of a woman her age with heart failure
nd an ICD is 14.9 years compared to 12.7 years if she
ent without an ICD implant. On the flip side, an 80-
ear-old male might choose to go without an ICD for
rimary prevention of sudden cardiac death, given the
nowledge that the life expectancy of a man his age suf-
ering from heart failure is 5 years, while the life expect-
ncy of a male his age with heart failure and an ICD im-
lant is only 6.2 years, taking into account the possibility
f ICD implant complications or even inappropriate
hocks (8).
A seldom appreciated benefit of shared decision-making
ay be better insight by the clinician into the risks and
enefits of treatment. For example, bleeding during PCI
s the most common noncardiac complication of the pro-
edure, and the NCDR has produced a valid risk model
or predicting bleeding complications after PCI (9). How-
ver, the model to date has not been used in clinical care,
nd a recent analysis of the NCDR has shown a risk-
reatment paradox, in which patients at the highest risk of
leeding are preferentially not treated with effective bleed- wng avoidance therapies, while those at the lowest risk for
leeding are (10). This is not only economically inefficient
using expensive interventions in those with the least po-
ential to benefit, while avoiding them in those with the
reatest potential to benefit), but it also worsens patient
afety. Deploying an estimate of patients’ bleeding risk at
he time of intervention can not only inform the patients
bout their risks, but could also be leveraged by physicians
o target bivalirudin, closure devices, or inpatient admis-
ions for closer observation after the procedure in those
ith moderate or high risk for periprocedural bleeding.
he College is currently partnering with others to deploy
ts risk models within a patient-centered, individualized
nformed consent process to assist both patients and their
hysicians (11).
If patients and physicians are to maximally benefit from
mproved medical decision-making, then several steps
eed to be taken. First, both clinical trials and registries
eed to start producing valid, clinically-useful risk predic-
ion models of patients’ outcomes (12). Second, more re-
earch into how best to incorporate access to these models
nto clinical care and how they should be presented to
atients and doctors needs to be performed. Finally, we
eed to recognize and reward the importance—and time
equired—to engage in shared decision-making. Toward
his end, payers need to embrace the importance of shared
ecision-making by reimbursing clinicians for the time and
esources needed to engage patients in an evidence-based
iscussion of their treatment options. An even more subtle
oint is that regulators need to appreciate that sometimes
ully-informed patients may not select those therapies de-
anded by current performance measures. While the ex-
lusions for some performance measures include patient-
entered reasons for not selecting therapy, documenting
hese is not easy and there are concerns that clinicians
ho do a better job of following patients’ preferences may
nadvertently appear to be performing lower-quality care.
ntil there is a system in place that rewards health care pro-
iders for quality outcomes and evidence-based care versus
he volume of care provided, this will continue to be a major
indrance to the shared decision-making model.
We have a ways to go before the shared decision-making
odel can be adopted on a national scale. That being
aid, the goals of shared decision making—to increase
atient knowledge; encourage patient involvement in deci-
ion making; facilitate more realistic expectations of treat-
ent options; and potentially reduce costs—are all ones
e can and should support.
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President’s Page December 7, 2010:2046–8Toward that end, the College strongly supports both the
pplication and research in the arena of shared decision-
aking. Our core values as cardiovascular professionals will
ontinue to move us forward with identifying the challenges
nd opportunities associated with shared decision-making, in
rder to ensure that future shared decision-making models
est meet the needs of patients and/or their families.
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